US20150013695A1 - Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same - Google Patents

Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same Download PDF

Info

Publication number
US20150013695A1
US20150013695A1 US14/327,137 US201414327137A US2015013695A1 US 20150013695 A1 US20150013695 A1 US 20150013695A1 US 201414327137 A US201414327137 A US 201414327137A US 2015013695 A1 US2015013695 A1 US 2015013695A1
Authority
US
United States
Prior art keywords
caffeine
composition
salt
inhalable
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/327,137
Other languages
English (en)
Inventor
Kelly McNeal
Brent Skoda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AHKEO LABS LLC
Original Assignee
Ahkeo Ventures LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ahkeo Ventures LLC filed Critical Ahkeo Ventures LLC
Priority to US14/327,137 priority Critical patent/US20150013695A1/en
Publication of US20150013695A1 publication Critical patent/US20150013695A1/en
Assigned to Ahkeo Ventures LLC reassignment Ahkeo Ventures LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MCNEAL, KELLY
Assigned to Ahkeo Ventures LLC reassignment Ahkeo Ventures LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SKODA, BRENT M.
Assigned to AHKEO LABS, LLC reassignment AHKEO LABS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Ahkeo Ventures LLC
Priority to US15/957,199 priority patent/US10632266B2/en
Priority to US16/859,241 priority patent/US20200338281A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/10—Chemical features of tobacco products or tobacco substitutes
    • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
    • A24F47/008—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/04—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised
    • A61M11/041—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters
    • A61M11/042—Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised using heaters electrical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/10—Devices using liquid inhalable precursors
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/40—Constructional details, e.g. connection of cartridges and battery parts
    • A24F40/42—Cartridges or containers for inhalable precursors
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/50—Control or monitoring

Definitions

  • the present technology generally relates to compositions, methods and an apparatus relating to the pulmonary delivery of an inhalable composition comprising caffeine.
  • Caffeine is a bitter substance that acts on many humans as a central nervous system stimulant, temporarily warding off drowsiness and restoring alertness. It is the most widely used of all psychoactive drugs. Caffeine consumption from all sources has been estimated at around 70 to 76 mg/person/day worldwide and about 210 to 238 mg/day in the US and Canada. In North America, 90% of adults consume caffeine daily. Daily caffeine consumption may reach a value of 2.4 to 4.0 mg/kg (170-300 mg) in a 60- to 70-kg individual, largely from coffee, tea, soft drinks, energy drinks, and chocolate foods. A cup of coffee, a soft drink or an energy drink can have about 80-200 mg, 30-60 mg or 60-280 mg caffeine per serving, respectively.
  • Caffeine is a hydrophobic compound with relatively low solubility in water.
  • the absorption of caffeine by the oral route, from the gastrointestinal tract, is rapid and reaches 99% in humans in about 45 minutes after ingestion.
  • the oral route has disadvantages.
  • the consumption of caffeine via soft drinks, energy drinks and chocolate foods contributes to weight gain and obesity.
  • the consumption of caffeine from coffee and tea contributes to stomach aches and gastrointestinal disorders.
  • Withdrawal symptoms after the discontinuation of caffeine from one's diet may include headache, irritability, inability to concentrate, drowsiness, insomnia, and pain in the stomach.
  • caffeine is needed. Also needed is an efficient means to administer caffeine more directly into the blood steam, relative to the oral route and without the concomitant consumption of foods and beverages that contain caffeine. For example, it would be desirable to provide improved methods and compositions for the pulmonary delivery of caffeine.
  • caffeinated powders have been developed for inhalation, these powders are ineffective because they settle on the tongue, mouth and throat of a subject where they are substantially rinsed into the stomach for oral delivery.
  • Electronic cigarettes such as electronic cigarettes have been developed for the pulmonary administration of relatively small concentrations of active compounds.
  • Electronic cigarettes which generally include a battery, vaporizer (i.e., atomizer), chamber to store the liquid and a mouthpiece, have been used to effectively vaporize actives such as nicotine for pulmonary administration.
  • the quantity of nicotine delivered by electronic cigarettes ranges from “low” doses of about 6-8 ⁇ g to “ultra high” doses of about 36-48 ⁇ g.
  • Described herein are improved compositions, methods and an apparatus relating to the pulmonary delivery of an inhalable composition comprising caffeine, or a salt thereof, and a solvent selected from the group consisting of propylene glycol, glycerol, ethanol, and a combination thereof.
  • Inhalable compositions have been developed that maintain caffeine, or a salt thereof, in aqueous solution and allow such aqueous solutions of caffeine to be heated and vaporized by an apparatus, such as a personal electronic vaporizer or an electronic cigarette, for pulmonary administration to a subject.
  • an apparatus such as a personal electronic vaporizer or an electronic cigarette
  • systemic absorption occurs through the thin layer of epithelial cells in the alveolar regions of the lung.
  • Such pulmonary delivery of caffeine may provide more rapid systemic availability than does the oral route and avoids stomach irritation and the need to consume foods or beverages that contain caffeine.
  • an inhalable composition comprising caffeine, or a salt thereof, and a solvent selected from the group consisting of propylene glycol, glycerol, ethanol, and a combination thereof.
  • the inhalable composition further comprises water.
  • Applicants have developed inhalable compositions having suitable ratios of propylene glycol, ethanol and glycerol that retain the caffeine in solution, such as an aqueous solution, and allow it to be efficiently vaporized.
  • Applicants have further developed such inhalable compositions having additional additives, some of which further improve the overall solubility of caffeine.
  • the inhalable composition comprises: about 1 wt.
  • % to about 10 wt % caffeine HCl about 1 wt. % to about 10 wt % yerba mate leaf extract, about 1 ⁇ 10 ⁇ 10 wt. % to about 1 ⁇ 10 ⁇ 5 wt % huperizine, about 1 wt. % to about 30 wt % taurine, about 1 wt. % to about 30 wt % inositol, about 0.1 wt. % to about 3 wt % niacinamide, about 1 wt. % to about 30 wt % phenylalanine, about 1 wt. % to about 30 wt % citicoline, about 1 wt. % to about 30 wt % propylene glycol, about 1 wt. % to about 30 wt % glycerol and water.
  • an apparatus for the pulmonary administration of an inhalable composition to a subject, wherein: the apparatus is a personal electronic vaporizer; the inhalable composition comprises caffeine, or a salt thereof, and a water-miscible solvent selected from the group consisting of propylene glycol, glycerol, ethanol and a combination thereof; and the apparatus comprises a means to store the inhalable composition as a liquid, a means to heat and transform the liquid into a vapor and a means to administer at least 0.0001 mg caffeine, or a salt thereof, from the vapor to the subject per inhalation by the subject from the apparatus.
  • the apparatus comprises the inhalable composition.
  • a method for administering an inhalable composition to a subject in need thereof comprising providing the subject with the inhalable composition comprising caffeine, or a salt thereof, and a solvent selected from the group consisting of propylene glycol, glycerol, ethanol and a combination thereof; and an apparatus for the pulmonary administration of the inhalable composition; wherein the method results in a pulmonary administration of at least 0.0001 mg of caffeine from the inhalable composition to the subject.
  • FIG. 1 is a top exterior view of an exemplary apparatus described herein, according to one illustrative implementation.
  • FIG. 2 is an interior view of an exemplary apparatus described herein, according to one illustrative implementation.
  • pulmonary delivery means that the mode of delivery targets the lungs of a subject as a means to enter the blood stream of the subject. Generally, not all of a given dosage that is administered by pulmonary delivery reaches both the lungs and the blood stream of the subject. Rather, just a fraction of the dosage that is administered by pulmonary delivery reaches both the lungs and the blood stream of the subject.
  • glycerol As used herein, the terms “glycerol,” “glycerin,” “vegetable glycerin” and “vegetable glycerol” are used interchangeably.
  • vapor is used to describe a droplet of liquid that is substantially free (e.g., at least 80-99% free) of solids.
  • water-miscible solvent is meant to include all solvents other than water that dissolve with water at a 1:1 ratio at 25° C.
  • the terms “personal electronic vaporizer” and “vaporizer” are meant to include all such devices, including and resembling electronic cigarettes that are known to those of ordinary skill in the art in addition to the personal electronic vaporizer apparatus that is disclosed herein.
  • Non-limiting representative electronic cigarettes are described in the published patent applications US 2012/0273589 and US 2012/0279512, both to Lik Hon.
  • active ingredient refers to a compound that provides a pharmacological activity.
  • active ingredients include, but are not limited to, caffeine, panax ginseng, gingko biloba, bitter orange, cola-nut, guarana, natrum carbonicum, green tea, cocoa extract, and yerba mate.
  • inactive ingredient refers to an inert compound or substance.
  • an inactive ingredient serves as a diluent or vehicle for the compound.
  • inactive ingredients include, but are not limited to, USP Kosher propylene glycol, USP Kosher vegetable glycerin, P57 Hoodia, ethanol, water, natural flavoring, inositol, and N-acetyl L tyrosine.
  • inhalable compositions comprising caffeine, or a salt thereof, and one or more water-miscible solvents, wherein the one or more water-miscible solvents each has a boiling point greater than 150° C.
  • the water-miscible solvent is selected from the group consisting of propylene glycol, glycerol, ethanol and a combination thereof.
  • the inhalable compositions are formulated for vaporization by an apparatus, such as a personal electronic vaporizer or electronic cigarette that stores the inhalable composition as a liquid, heats the inhalable composition into a vapor phase and delivers the inhalable composition to the subject as a vapor via inhalation.
  • an apparatus such as a personal electronic vaporizer or electronic cigarette that stores the inhalable composition as a liquid, heats the inhalable composition into a vapor phase and delivers the inhalable composition to the subject as a vapor via inhalation.
  • caffeine bypasses acid and bile in the stomach, and is expected to reach the central nervous system sooner than the oral route. It is contemplated that the inhalable compositions described herein will not cause stomach aches that can occur following the consumption of coffee or tea.
  • the inhalable compositions described herein include caffeine, or a salt thereof, and a water-miscible solvent, particularly those selected from the group consisting of propylene glycol, glycerol, ethanol and a combination thereof.
  • a water-miscible solvent particularly those selected from the group consisting of propylene glycol, glycerol, ethanol and a combination thereof.
  • Propylene glycol, having a boiling point of 188.2° C. and glycerol having a boiling point of 290° C. act as solvents and as thickening agents.
  • Propylene glycol, glycerol and ethanol also provide a relatively even heating of the inhalable composition as it is vaporized by the apparatus.
  • propylene glycol, glycerol and ethanol provide tangible plumes of vapor that retain the caffeine within the vapor droplets.
  • the quantity of propylene glycol that is added to the inhalable compositions described herein can and will vary.
  • the inhalable compositions described herein comprise 0 wt. %, 1 wt. %, 2 wt. %, 3 wt. %, 4 wt. %, 5 wt. %, 6 wt. %, 7 wt. %, 8 wt. %, 9 wt. %, 9.5 wt. %, 10 wt. %, 10.5 wt. %, 11 wt. %, 12 wt. %, 13 wt. %, 14 wt. %, 15 wt. %, 16 wt.
  • the inhalable composition comprises propylene glycol and does not contain glycerol.
  • the quantity of glycerol that is added to the inhalable compositions described herein can and will vary.
  • the inhalable compositions described herein comprise 0 wt. %, 1 wt. %, 2 wt. %, 3 wt. %, 4 wt. %, 5 wt. %, 6 wt. %, 7 wt. %, 8 wt. %, 9 wt. %, 9.5 wt. %, 10 wt. %, 10.5 wt. %, 11 wt. %, 12 wt. %, 13 wt. %, 14 wt. %, 15 wt. %, 16 wt.
  • the inhalable composition comprises glycerol and does not contain propylene glycol.
  • the quantity of ethanol that is added to the inhalable compositions described herein can and will vary.
  • the inhalable compositions described herein comprise 0 wt. %, 1 wt. %, 2 wt. %, 3 wt. %, 4 wt. %, 5 wt. %, 6 wt. %, 7 wt. %, 8 wt. %, 9 wt. %, 9.5 wt. %, 10 wt. %, 10.5 wt. %, 11 wt. %, 12 wt. %, 13 wt. %, 14 wt. %, 15 wt. %, 16 wt.
  • the inhalable composition comprises ethanol and does not contain glycerol or propylene glycol.
  • the inhalable composition described herein comprises propylene glycol and glycerol, each in any of the wt % amounts described herein, such that the inhalable composition has a wt/wt % ratio of propylene glycol to glycerol (i.e., propylene glycol:glycerol) of 1:1,000, 1:500, 1:100, 1:50, 1:25, 1:20, 1:15, 1:10, 1:5, 1:4, 1:3, 1:2, 1.1.5, 1:1.4, 1:1.3, 1:1.2, 1:1.1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 15:1, 20:1, 25:1, 50:1, 100:1, 1,000:1 or a ration between any two of these values.
  • the inhalable composition comprises propylene glycol and glycerol, and the inhalable composition has a ratio of propylene glycol to glycerol of about 2:1 to about
  • the inhalable composition described herein comprises propylene glycol and ethanol, each in any of the wt % amounts described herein, such that the inhalable composition has a wt/wt % ratio of propylene glycol to ethanol (i.e., propylene glycol:ethanol) of 1:1,000, 1:500, 1:100, 1:50, 1:25, 1:20, 1:15, 1:10, 1:5, 1:4, 1:3, 1:2, 1.1.5, 1:1.4, 1:1.3, 1:1.2, 1:1.1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 15:1, 20:1, 25:1, 50:1, 100:1, 1,000:1 or a ration between any two of these values.
  • the inhalable composition comprises propylene glycol and ethanol, and the inhalable composition has a ratio of propylene glycol to ethanol of about 2:1 to about 1:2.
  • the inhalable composition described herein comprises ethanol and glycerol, each in any of the wt % amounts described herein, such that the inhalable composition has a wt/wt % ratio of ethanol to glycerol (i.e., ethanol:glycerol) of 1:1,000, 1:500, 1:100, 1:50, 1:25, 1:20, 1:15, 1:10, 1:5, 1:4, 1:3, 1:2, 1.1.5, 1:1.4, 1:1.3, 1:1.2, 1:1.1, 1:1, 1.1:1, 1.2:1, 1.3:1, 1.4:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 15:1, 20:1, 25:1, 50:1, 100:1, 1,000:1 or a ration between any two of these values.
  • the inhalable composition comprises ethanol and glycerol, and the inhalable composition has a ratio of ethanol to glycerol of about 2:1 to about 1:2.
  • the inhalable composition described herein comprises propylene glycol, ethanol, and glycerol, each in any of the wt % amounts described herein.
  • the inhalable composition further comprises water.
  • the inhalable composition described herein comprises 0 wt. %, 1 wt. %, 2 wt. %, 3 wt. %, 4 wt. %, 5 wt. %, 6 wt. %, 7 wt. %, 8 wt. %, 9 wt. %, 9.5 wt. %, 10 wt. %, 10.5 wt. %, 11 wt. %, 12 wt. %, 13 wt. %, 14 wt. %, 15 wt. %, 16 wt. %, 17 wt.
  • the inhalable composition described herein is a vapor comprising liquid droplets.
  • the liquid droplets have an average diameter that facilitates administration of the caffeine within the droplets to the subject via the pulmonary route.
  • the liquid droplets may have an average diameter of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 microns, or an average diameter between any two of these values.
  • the inhalable compositions described herein further comprise suitable additives.
  • the inhalable composition further comprises one or more additives such as yerba mate leaf extract, huperizine, taurine, inositol, niacinamide, phenylalanine, citicoline, or a salt of any thereof.
  • Yerba Mate extract is the product of yerba mate plant brewed or distilled so that caffeine (or maffeine) is left in the residue.
  • the absorption rate of maffeine through the body is slower than that of caffeine and may produce a more uplifting feeling than caffeine.
  • Huperzine A may cause an increase in the levels of acetylcholine in a subject.
  • Huperzine A may also offset the negative jitteriness that caffeine may cause in a subject.
  • Taurine has been found to help dissolve the caffeine in the inhalable compositions described herein and may also help to facilitate the absorption of caffeine into the blood. Taurine may also minimize the caffeine crash that occurs in some patients following administration of caffeine.
  • Taurine may also serve as a relaxant to offset the jitteriness caused by caffeine and help a subject go to sleep.
  • Inositol is a flavorant that improves the taste of inhalable compositions comprising caffeine. Specifically, it reduces the bitterness of caffeine. Inositol has also been found improve the solubility of caffeine in the inhalable compositions described herein.
  • Niacinamide also known as vitamin B-3, plays important roles in the energy production process in cells. Niacinamide boosts the effects of caffeine to create longer lasting stimulation in a subject. Niacinamide may also help reduce the “short of breath” feeling that some people complain of after ingesting caffeine. Phenylalanine may reduce caffeine headache associated with caffeine and may also help with caffeine withdrawal.
  • Citicoline may play a role in neurotransmission and might help support brain function.
  • suitable additives include, but are not limited to, N-Acetyl L Tyrosine, Panax Ginseng ( Aralia quinquefolia ), Gingko Biloba ( Ginkgo biloba L.), Bitter Orange ( Citrus aurantium L.), Cola-Nut ( Cola acuminate ), Guarana ( Paullinia cupana ), Natrum Carbonicum, Green Tea ( Camellia sinensis ), Cocoa Extract ( Theobroma cacao L.), Licorice ( Glycyrrhiza glabra L.), Natrum Carbonicum, Ginger ( Zingiber officinale Rosc.), P57 Hoodia, Glucuronolactone, Yerba Mate ( Ilex paraguensis St. Hil.), Garcinia Cambogia, Hoodia Gordonii, Kelp, and Peppermint ( Mentholum ).
  • the additional additives are useful for energy and/or diet support.
  • the additional additives are natural flavoring.
  • the inhalable composition comprises about 1 wt. % to about 10 wt % caffeine HCl, about 1 wt. % to about 10 wt % yerba mate leaf extract, about 1 ⁇ 10 ⁇ 10 wt. % to about 1 ⁇ 10 ⁇ 5 wt % huperizine, about 1 wt. % to about 30 wt % taurine, about 1 wt. % to about 30 wt % inositol, about 0.1 wt. % to about 3 wt % niacinamide, about 1 wt. % to about 30 wt % phenylalanine, about 1 wt. % to about 30 wt % citicoline, about 1 wt. % to about 30 wt % propylene glycol, about 1 wt. % to about 30 wt % glycerol, and water.
  • the inhalable composition comprises about 1-5 wt % caffeine HCl, about 1-5 wt % yerba mate leaf extract, about 1 ⁇ 10 ⁇ 9 to 1 ⁇ 10 ⁇ 6 wt % huperizine, about 1-15 wt % taurine, about 1-15 wt % inositol, about 0.1-2.0 wt % niacinamide, about 1-15 wt % phenylalanine, about 1-15 wt % citicoline, about 1-15 wt % propylene glycol, about 1-15 wt % glycerol, and water.
  • the water is de-ionized water.
  • the inhalable composition comprises about 3.8 wt % caffeine HCl, about 2.5 wt % yerba mate leaf extract, about 1 ⁇ 10 ⁇ 8 wt % huperizine, about 9.5 wt % taurine, about 9.5 wt % inositol, about 0.6 wt % niacinamide, about 9.5 wt % phenylalanine, about 7.6 wt % citicoline, about 9.5 wt % propylene glycol, about 9.5 wt % glycerol, and water.
  • the water is de-ionized water.
  • the inhalable composition further comprises about 1 wt %, 5 wt %, 10 wt %, 15 wt %, 20 wt %, 25 wt %, 30 wt %, or a range between any two of these values, of a flavorant.
  • the flavorant may be selected from the group consisting of citric acid, lemon extract, lime extract, orange extract, peppermint, spearmint, cinnamon and a combination thereof.
  • the inhalable composition further comprises nicotine.
  • the inhalable composition described herein comprises 0 wt. %, 0.1 wt. %, 0.2 wt. %, 0.3 wt. %, 0.4 wt. %, 0.5 wt. %, 1 wt. %, 2 wt. %, 5 wt. %, or a percentage between any two of these values of nicotine relative to the of the entire inhalable composition comprising caffeine.
  • the inhalable compositions and formulations described herein are for the pulmonary administered to a subject (e.g., a human) and may contain one or more pharmaceutically-acceptable excipients, or carriers. Suitable excipients and their formulations are described in Remington's Pharmaceutical Sciences, 16th ed., 1980, Mack Publishing Co., edited by Oslo et al. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable excipients include liquids such as saline, Ringer's solution and dextrose solution.
  • the pH of the formulation can be set at any desired level which is not damaging to lung surfaces. Although it is desirable to have a low pH formulation (acidic) to avoid interaction with certain types of plastic containers it is generally more desirable to have a high pH formulation (basic) to increase the absorption of the caffeine from the lung into the circulatory system.
  • the pH of the inhalable compositions described herein is generally from about 3 to about 8, or from about 3 to about 7, although the pH may be varied.
  • the inhalable composition or formulation may also comprise a lyophilized powder or other optional excipients suitable to the present inhalable composition or formulation including sustained release preparations known to those of skill in the art.
  • the inhalable compositions or formulations described herein for inhalation can include, e.g., one or more surfactants to aid in solubility and stability of formulation constituents.
  • surfactants can be present in formulations of the invention in a concentration ranging from about 0.001 weight percent to about 2 weight percent, or about 0.01 weight percent to about 1 weight percent.
  • the surfactants can include, e.g., nonionic detergents, such as polyethylene glycol sorbitan monolaurate (Tween 20), polyoxyethylenesorbitan monooleate (Tween 80), block copolymers of polyethylene and polypropylene glycol (Pluronic), non-ionic surfactants, ionic surfactants and/or the like.
  • nonionic detergents such as polyethylene glycol sorbitan monolaurate (Tween 20), polyoxyethylenesorbitan monooleate (Tween 80), block copolymers of polyethylene and polypropylene glycol (Pluronic), non-ionic surfactants, ionic surfactants and/or the like.
  • non-ionic surfactants are alkylphenyl alkoxylates, alcohol alkoxylates, fatty amine alkoxylates, polyoxyethylene glycerol fatty acid esters, castor oil alkoxylates, fatty acid alkoxylates, fatty acid amide alkoxylates, fatty acid polydiethanolamides, lanolin ethoxylates, fatty acid polyglycol esters, isotridecyl alcohol, fatty acid amides, methylcellulose, fatty acid esters, silicone oils, alkyl polyglycosides, glycerol fatty acid esters, polyethylene glycol, polypropylene glycol, polyethylene glycol/polypropylene glycol block copolymers, polyethylene glycol alkyl ethers, polypropylene glycol alkyl ethers, polyethylene glycol/polypropylene glycol ether block copolymers and mixtures of these, polyacrylates and acrylic acid graft copolymers, poly
  • nonionic surfactants are known per se to those skilled in the art and have been described in the literature.
  • Preferred substances are polyethylene glycol, polypropylene glycol, polyethylene glycol/polypropylene glycol block copolymers, polyethylene glycol alkyl ethers, polypropylene glycol alkyl ethers, polyethylene glycol/polypropylene glycol ether block copolymers and mixtures of these.
  • Particularly preferred surfactants include polymers of a mixture of polyoxyethylene and polyoxypropylene such as Pluronic F68 (available from BASF).
  • Suitable ionic surfactants are alkylarylsulfonates, phenylsulfonates, alkyl sulfates, alkyl sulfonates, alkyl ether sulfates, alkyl aryl ether sulfates, alkyl polyglycol ether phosphates, polyaryl phenyl ether phosphates, alkylsulfosuccinates, olefin sulfonates, paraffin sulfonates, petroleumsulfonates, taurides, sarcosides, fatty acids, alkylnaphthalenesulfonic acids, naphthalenesulfonic acids, lignosulfonic acids, condensates of sulfonated naphthalenes with formaldehyde or with formaldehyde and phenol and, if appropriate, urea, lignin-sulfite waste liquor, including their alkali metal, al
  • the inhalable compositions and formulations described herein may include one or more buffers.
  • Buffers can be present, e.g., to control pH, enhance stability, affect constituent solubility, provide comfort on administration, and the like.
  • Formulation pH can be controlled in the range from about pH 3 to about pH 10, from about pH 6 to about pH 8, from about pH 7 to about pH 7.4, or about pH 7.2.
  • Preferred buffers are often paired acid and salt forms of a buffer anion generally recognized as safe for the particular route of administration of the bioactive material.
  • Typical buffers for use in the formulations and inhalable compositions of the invention include, e.g., potassium phosphate, sodium phosphate, sodium acetate, histidine, imidazole, sodium citrate, sodium succinate, ammonium bicarbonate, carbonates, and the like.
  • buffers are used at molarities from about 1 mM to about 2 M, with from about 2 mM to about 1 M being preferred, and from about 10 mM to about 0.5 M being especially preferred, and 25 mM to 50 mM being particularly preferred.
  • any of the inhalable compositions described herein comprises propylene glycol, glycerol, ethanol, or a combination thereof they are generally more viscous than water.
  • any of the inhalable compositions described herein has a viscosity at 20° C. of about 0.001 Pa ⁇ s, about 0.01 Pa ⁇ s, about 0.1 Pa ⁇ s, about 1.0 Pa ⁇ s, about 1.5 Pa ⁇ s, or a viscosity between any two of the these values.
  • the inhalable compositions described herein are formulated to provide at least 0.0001 mg of caffeine to a subject per inhalation of any one of these compositions.
  • the inhalable compositions described herein may be formulated to provide at least about 0.0001, 0.001, 0.01, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 100, 105, 110, 125, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300 mg, or an amount between any two of these values, of caffeine or a salt thereof, to the subject per inhalation (i.e.
  • the composition is formulated to provide about 0.0001 mg to about 10 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 10 mg to about 20 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 20 mg to about 30 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 30 mg to about 40 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 40 mg to about 50 mg of caffeine or a salt thereof to the subject per inhalation by the subject.
  • the composition is formulated to provide about 50 mg to about 60 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 60 mg to about 70 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 70 mg to about 80 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 80 mg to about 90 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 90 mg to about 100 mg of caffeine or a salt thereof to the subject per inhalation by the subject.
  • the composition is formulated to provide about 100 mg to about 110 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 110 mg to about 120 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 120 mg to about 130 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 130 mg to about 140 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 140 mg to about 150 mg of caffeine or a salt thereof to the subject per inhalation by the subject.
  • the composition is formulated to provide about 150 mg to about 160 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 160 mg to about 170 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 170 mg to about 180 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 180 mg to about 190 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 190 mg to about 200 mg of caffeine or a salt thereof to the subject per inhalation by the subject.
  • the composition is formulated to provide about 200 mg to about 210 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 210 mg to about 220 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 220 mg to about 230 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 230 mg to about 240 mg of caffeine or a salt thereof to the subject per inhalation by the subject.
  • the composition is formulated to provide about 240 mg to about 250 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 250 mg to about 260 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 260 mg to about 270 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 270 mg to about 280 mg of caffeine or a salt thereof to the subject per inhalation by the subject.
  • the composition is formulated to provide about 280 mg to about 290 mg of caffeine or a salt thereof to the subject per inhalation by the subject. In some embodiments, the composition is formulated to provide about 290 mg to about 300 mg of caffeine or a salt thereof to the subject per inhalation by the subject.
  • the inhalable compositions described herein are formulated to provide less than 1 mg of nicotine to a subject per inhalation of any one of these compositions.
  • the inhalable compositions described herein may be formulated to provide at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45 or 50 ⁇ g, or an amount between any two of these values, of nicotine or a salt thereof, to the subject per inhalation (i.e., vape).
  • the inhalable compositions of the present technology includes one or more active ingredients selected from the group consisting of Caffeine ( Caffeinum ), Panax Ginseng ( Aralia quinquefolia ), Gingko Biloba ( Ginkgo biloba L.), Bitter Orange ( Citrus aurantium L.), Cola-Nut ( Cola acuminate ), Guarana ( Paullinia cupana ), Natrum Carbonicum, Green Tea ( Camellia sinensis ), Cocoa Extract ( Theobroma cacao L.), and Yerba Mate ( Ilex paraguensis St. Hil.).
  • Caffeine Caffeinum
  • Panax Ginseng Aralia quinquefolia
  • Gingko Biloba Ginkgo biloba L.
  • Bitter Orange Citrus aurantium L.
  • Cola-Nut Cola acuminate
  • Guarana Paullinia cupana
  • Natrum Carbonicum Green Tea
  • Camellia sinensis Cocoa Extract
  • the inhalable composition also includes one or more inactive ingredients selected from the group consisting of USP Kosher propylene glycol, USP Kosher vegetable glycerin, ethanol, water, glucuronolactone, natural flavoring, inositol, and N-acetyl L tyrosine.
  • the inhalable composition provides energy.
  • the inhalable compositions of the present technology includes one or more active ingredients selected from the group consisting of Caffeine ( Caffeinum ), Peppermint ( Mentholum ), Bitter Orange ( Citrus aurantium L.), Green Tea ( Camellia sinensis ), Licorice ( Glycyrrhiza glabra L.), Natrum Carbonicum, Ginger ( Zingiber officinale Rosc.), Garcinia Cambogia, Hoodia Gordonii, Kelp, and Yerba Mate ( Ilex paraguensis St. Hil.).
  • active ingredients selected from the group consisting of Caffeine ( Caffeinum ), Peppermint ( Mentholum ), Bitter Orange ( Citrus aurantium L.), Green Tea ( Camellia sinensis ), Licorice ( Glycyrrhiza glabra L.), Natrum Carbonicum, Ginger ( Zingiber officinale Rosc.), Garcinia Cambogia, Hoodia Gordonii, Kelp, and Yerb
  • the inhalable composition also includes one or more inactive ingredients selected from the group consisting of USP Kosher propylene glycol, USP Kosher vegetable glycerin, P57 Hoodia, ethanol, water, natural flavoring, inositol, and N-acetyl L tyrosine.
  • the inhalable composition provides energy.
  • the inhalable composition provides diet support.
  • FIG. 1 is a top view of an exemplary implementation of a vaporizer apparatus 100 (also referred to as a vaporizer 100 ).
  • the exterior of the vaporizer 100 may include the body section 102 and the mouthpiece 104 .
  • the body 104 of the vaporizer 100 may store the components that are responsible for the function and control of the vaporizer 100 .
  • the mouthpiece 104 may house the cartridge used to store the inhalable composition.
  • the vaporizer 100 delivers a predetermined amount of the inhalable composition to the user in a vapor form.
  • FIG. 2 is a side view of the vaporizer 100 .
  • FIG. 2 illustrates an exemplary configuration of the layout of components within the vaporizer 100 .
  • the vaporizer 100 may include a cartridge 106 , an atomizer 108 , a controller 110 , and a power supply 112 .
  • the cartridge 106 may be configured to house any of the inhalable composition described herein.
  • the inhalable composition includes an additive selected from the group consisting of yerba mate leaf extract, huperizine, taurine, inositol, niacinamide, phenylalanine, citicoline, or a salt of any thereof, and a combination thereof.
  • the housing of the cartridge 106 may be made from any food grade material.
  • the housing of the cartridge 106 may include polyethylene terephthalate, high density polyethylene, polyvinyl chloride, or any combination thereof.
  • the housing of the cartridge 106 may include metals or allows.
  • the cartridge 106 is configured to allow the inhalable composition to pass to the atomizer 108 in a liquid form and then pass through the mouthpiece 104 to the user in a vapor form.
  • the cartridge 106 may include an air-liquid separator which allows the inhalable composition to exit the mouthpiece 104 in substantially only vapor form and not liquid form.
  • the air-liquid separator is a sponge or membrane.
  • the cartridge 106 is refillable and in some implementations the cartridge 106 is disposed of once the inhalable composition is consumed.
  • the cartridge 106 may be a component of, or coupled to the mouthpiece 104 , such that the mouthpiece 104 section may be replaced when replacing the cartridge 106 .
  • the mouthpiece 104 and/or the body 102 (and components housed within the body 102 ) of the vaporizer 100 may be reusable. For example, once the inhalable composition within the cartridge 106 has been consumed, a user may replace the cartridge 106 and continue using the vaporizer 100 .
  • the vaporizer 100 may be disposed of after the inhalable composition in the cartridge 106 is consumed.
  • the cartridge 106 may be configured to store an inhalable composition that includes between about 0.0001 mg and about 10 mg, between about 0.001 mg and about 5 mg, between about 0.01 mg and about 2.5 mg, or between about 0.1 mg and 1.0 mg of caffeine in solution. In some implementation, the cartridge 106 may be configured to store an inhalable composition that includes between about 10 mg and about 200 mg, between about 30 mg and about 180 mg, between about 50 mg and about 160 mg, between about 70 mg and about 140 mg, between about 90 mg and about 120 mg, or between about 100 mg and about 110 mg of caffeine in solution.
  • the cartridge 106 may be configured to store an inhalable composition that includes between about 200 mg and about 2000 mg, between about 400 mg and about 1800 mg, between about 600 mg and about 1600 mg, between about 800 mg and about 1400 mg, or between about 1000 mg and about 1200 mg of caffeine in solution.
  • the cartridge 106 may be coupled to the atomizer 108 such that between about 0.0001 mg and about 5 mg, between about 5 mg and 15 mg, between about 15 mg and 25 mg, between about 25 mg and 30 mg, between about 30 mg and 35 mg, between about 35 mg and 40 mg, between about 40 mg and 45 mg, between about 45 mg and 50 mg, between about 50 mg and 55 mg, between about 55 mg and 60 mg, between about 60 mg and 65 mg, between about 65 mg and 70 mg, between about 70 mg and 85 mg, between about 85 mg and 90 mg, between about 90 mg and 95 mg, between about 95 mg and 100 mg, between about 100 mg and 105 mg, between about 105 mg and 110 mg, between about 110 mg and 120 mg, between about 120 mg and 130 mg, between about 130 mg and 140 mg, between about 140 mg and 150 mg, between about 150 mg and 160 mg, between about 160 mg and 170 mg, between about 170 mg and 180 mg, between about 180 mg and 190 mg, between about 190 mg and 200 mg, between about 200 mg and 210 mg, between about 210
  • the coupling between the cartridge 106 and the atomizer 108 may include a fluid flow channel.
  • the inhalable composition may be drawn into the atomizer 108 through capillary action.
  • a wicking metal such as silica, may draw the liquid inhalable composition from the cartridge 106 to the atomizer 108 .
  • the atomizer 108 vaporizes the inhalable composition.
  • the atomizer 108 may include a heating element that heats and vaporizes the inhalable composition.
  • the atomizer 108 may heat the inhalable compositions comprising caffeine, or a salt thereof, and a solvent selected from the group consisting of propylene glycol, glycerol, ethanol and a combination thereof, to form a vapor.
  • the atomizer 108 heats the inhalable composition into a vapor at about 250° F., 300° F., 350° F., 400° F., 450° F., 500° F., 550° F., or a temperature between any two of these values.
  • the vaporizer 100 is an electronic cigarette.
  • the vaporized inhalable composition may be referred to as a vapor and may include liquid droplets of caffeine, which may be inhaled by the user.
  • the size distribution of the diameter of the vapor droplets that are delivered by the apparatus is important to the therapeutic efficacy of the caffeine within the inhalable composition when delivered by inhalation.
  • Liquid droplets of greater than about 20 micrometers in mean aerodynamic diameter generally achieve reduced entry into the lungs and are captured in the nasal-pharyngeal passages.
  • the caffeine compositions for inhalation, as described herein, to be delivered via pulmonary administration are generally formulated so that the median aerodynamic diameter of the vapor droplets is below about 10 micrometers.
  • the size distribution of the diameter of the vapor droplets is within a size range of about between about 0.5, 1, 2.5, 10, 20 microns in diameter.
  • Droplet size may be selected to stimulate either the upper respiratory tract or the lower respiratory tract or both.
  • the vapor and each inhalation thereof may contain caffeine in an amount of about 0.0001 mg to about 20.0 mg per inhalation.
  • the vaporizer 100 includes a porous membrane.
  • the rate and amount of caffeine that can be absorbed can be varied by changing the constituent (e.g., caffeine, propylene glycol, glycerol and/or ethanol) concentration of and/or pH of the caffeine inhalable composition in the packets.
  • the pore size is in a preferred range then a relatively high amount of the formulation, when aerosolized, will reach the subject's deep lungs and rapidly move from the lungs into the subject's circulatory system.
  • the pores larger the aerosolized droplets created also become larger.
  • the larger droplets will not move into the deep lungs as efficiently as the smaller droplets.
  • a significant number of droplets with aerodynamic size greater than 5 micron would deposit in the oropharynx from where they are not rapidly absorbed into the subject's circulatory system.
  • the vaporizer 100 described herein can be configured to target certain areas of the respiratory tract with the inhalable compositions described herein, it will be understood by those skilled in the art that it will not be possible to provide an apparatus which exclusively administers droplets only to a particular area of a respiratory tract. In general, smaller size droplets will deposit in the lung more deeply as compared to larger size droplets. Further, it is generally not desirable to make the droplets smaller than 0.5 microns. When the droplets are sufficiently small, they can be inhaled and exhaled back out without being deposited at all, unless the subject holds their breath for sufficient length of time, typically several seconds, for those droplets to deposit.
  • droplets which are larger than this size generally deposit very high up in the respiratory tract and as such do not reach the blood quickly.
  • vaporized droplets often do not have a stable size. For example, droplets can pick up moisture from the air in the respiratory tract and grow in size. Volatile components of droplets can evaporate and make the droplet size smaller. These changes may also cause changes in the density of the droplets that affects their aerodynamic size.
  • the atomizer 108 may be coupled to the controller 110 and/or the power supply 112 .
  • the controller 110 may include a microprocessor.
  • the controller 110 may also include computer readable media on which processor executable instructions are stored. When executed by the microprocessor, the instructions may cause the microprocessor heat the atomizer 108 to one of the above described predetermined temperatures in order to vaporize the inhalable composition. Additionally, and as described further below, the controller 110 may also regulate the amount of caffeine that a user may ingest.
  • the controller 110 may control the activation of the atomizer 108 , and thus the dosage of caffeine that is delivered to a user.
  • the controller 110 may include a flow sensor, which may detect the inhalation of a user and activate the atomizer 108 .
  • the controller 110 may activate the atomizer 108 when the user activates a button or other switch located on the vaporizer 100 .
  • the controller 110 allows the user to select what temperature the atomizer 108 heats the liquid inhalable composition.
  • the processor executable instructions may cause the controller 110 to limit or control the amount of caffeine and/or inhalable composition a user may ingest.
  • the controller 112 provides a delay of about 4 to 10 seconds between inhalations (i.e., vapes). The delay may promote the safety of the user.
  • the user may require from about 1 to about 40 vapes to administer an effective dose of caffeine equivalent to that found in a cup of coffee (e.g., about 200 mg of caffeine).
  • the controller may allow the vaporizer 100 to administer at least 0.0001 mg caffeine, or a salt thereof, such as about 2 mg to about 50 mg, from the vaporizer 100 to the user per inhalation by the user.
  • the vaporizer 100 described herein can be used to administer one or more inhalations to a user to achieve an effective dose of approximately 20, 40, 60, 80, 100, 200 mg or more of caffeine to a subject over the course of one or more inhalations from the vaporizer 100 by the user.
  • the controller 110 may cause the vaporizer 100 to enter a refractory state for a predetermined amount of time after the administration of one or more vapes. During the refractory period, the controller 110 may not allow the vaporizer 100 to administer additional vapes to the user. For example, after a user draws two inhalations, the controller 110 may not allow another inhalation to be drawn from the vaporizer 100 for 4 hours.
  • the predetermined amount of time may be between about 15 minutes and about 30 minutes, between about 30 minutes and about 1 hour, between about 1 hour and about 4 hours, between about 4 hours and about 8 hours, and between about 8 hours and about 24 hours.
  • the controller 110 may limit the number of vapes (or caffeine) that may be administered within a predetermined time window.
  • the vaporizer 100 may not enter a refractory state until a predetermined number of vapes have been administered.
  • the controller 110 may allow the user to draw 10 vapes over the course of one hour.
  • the predetermined amount of time may be between about 15 minutes and about 30 minutes, between about 30 minutes and about 1 hour, between about 1 hour and about 4 hours, between about 4 hours and about 8 hours, and between about 8 hours and about 24 hours.
  • control sequences may be used to limit the amount of caffeine that a user is allowed to consume via the vaporizer 100 .
  • the controller 110 may control the inter-vape timing, the amount of caffeine per vape, and the amount of caffeine in a dosage cycle (i.e., the amount of caffeine that a user is allowed to ingest over a given predetermined time window).
  • the controller 110 may limit the amount of caffeine in a dosage cycle to between about 0.0001 mg and about 5 mg, between about 5 mg and about 15 mg, between about 15 mg and about 50 mg, between about 50 mg and about 100 mg, between about 100 mg and about 500 mg of caffeine, and, as described above, the predetermined amount of time may range from 15 minutes to 24 hours.
  • controller 110 may include analog circuitry and the control methods described herein may implemented with analog logic and/or digital logic.
  • the vaporizer 100 is powered by a power supply 112 .
  • the power supply 112 is a battery.
  • the battery may be a rechargeable battery, such as a lithium ion battery.
  • the battery may be recharged without removing the battery from the vaporizer 100 .
  • the power supply 112 may be a non-rechargeable battery.
  • the power supply 112 may include an AC (alternating current) adapter that allows the vaporizer 100 to be powered by alternating current (e.g., power from a wall outlet).
  • the power supply 112 may provide between about 3 V and 9 V of electricity of the vaporizer 100 .
  • a method for administering an inhalable composition to a subject in need thereof comprising providing the subject with: (a) the inhalable composition comprising caffeine, or a salt thereof, and a solvent selected from the group consisting of propylene glycol, glycerol, ethanol and a combination thereof; and (b) an apparatus for the pulmonary administration of the inhalable composition; wherein the method results in a pulmonary administration of at least 0.0001 mg of caffeine from the inhalable composition to the subject.
  • the method further comprises instructing the subject to inhale the inhalable composition from the apparatus.
  • the inhalable composition is any of the inhalable compositions described herein.
  • the inhalable composition may further comprise yerba mate leaf extract, huperizine, taurine, inositol, niacinamide, phenylalanine, citicoline, or a salt of any thereof, propylene glycol, glycerol, ethanol and water.
  • the inhalable composition comprises: about 3.8 wt % caffeine HCl, about 2.5 wt % yerba mate leaf extract, about 1 ⁇ 10 ⁇ 8 wt % huperizine, about 9.5 wt % taurine, about 9.5 wt % inositol, about 0.6 wt % niacinamide, about 9.5 wt % phenylalanine, about 7.6 wt % citicoline, about 9.5 wt % propylene glycol, about 9.5 wt % glycerol, and water.
  • about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45 or 50 mg, or an amount between any two of these values, of caffeine or a salt thereof is inhaled by the subject per inhalation (i.e., vape).
  • the subject per inhalation i.e., vape
  • about 0.0005 mg to about 10 mg of caffeine or a salt thereof is inhaled by the subject per inhalation.
  • about 10 mg to about 20 mg of caffeine or a salt thereof is inhaled by the subject per inhalation.
  • about 20 mg to about 30 mg of caffeine or a salt thereof is inhaled by the subject per inhalation.
  • about 30 mg to about 40 mg of caffeine or a salt thereof is inhaled by the subject per inhalation. In some embodiments of the method, about 40 mg to about 50 mg of caffeine or a salt thereof is inhaled by the subject per inhalation.
  • the composition further comprises nicotine or a salt thereof.
  • nicotine or a salt thereof.
  • less than 1 mg of nicotine is provided to a subject per inhalation of any one of these compositions.
  • the composition is inhaled from the apparatus as a vapor comprising liquid droplets.
  • the droplets have an average diameter of about 0.5, 1, 2.5 10, or 20 microns, or a diameter between any two of these values.
  • the vapor is formed at about 250° F., 300° F., 350° F., 400° F., 450° F., 500° F., 550° F., or a temperature between any two of these values.
  • the apparatus is an electronic vaporizer, such as an electronic cigarette. In one embodiment of the method, the apparatus is any apparatus as described herein.
  • a method of treatment comprising: (a) aerosolizing any one of the inhalable compositions or formulations comprised of caffeine, or a salt thereof, as described herein, creating aerosolized droplets which are sufficiently small as to enter the alveolar ducts; (b) allowing a subject to inhale the aerosolized droplets of (a) thereby causing caffeine, or a salt thereof, to enter the patient's blood at air/blood diffusion membranes.
  • the method further comprises: (c) repeating (a) and (b) a plurality of times.
  • Inhalable Formulations D-N are allowed to stand at room temperature for 24 hours and examined for signs of precipitation or emulsification. Inhalable Formulations D-N are then added to an electronic vaporizer (e.g., electronic cigarette) known in the art or as described herein. Each of Formulations D-N is separately vaporized in a quantity that simulates a “vape” i.e., the amount of vapor that will be inhaled by a subject from an electronic vaporizer. The resulting vapors are captured. The captured vapors are diluted with water, the caffeine is precipitated from solution, collected and quantified. It is contemplated that some or all of Formulations D-N will deliver at least 0.0001 mg of caffeine or a salt thereof per vape.
  • an electronic vaporizer e.g., electronic cigarette
  • An electronic vaporizer e.g., electronic cigarette
  • An electronic vaporizer known in the art or described herein may be used to deliver single-bolus doses of Inhalable Composition B to healthy adults.
  • a substantially uniform aerosol is created when the Inhalable Composition B solution is vaporized by the electronic vaporizer.
  • the fine aerosol that is generated allows the deep-lung deposition needed to achieve rapid and efficient absorption of caffeine.
  • Study Part 1 the tolerability and safety of Inhalable Formulation B is evaluated.
  • Study Part 2 subjects received one of three caffeine concentrations (from Formulations A, B and C), delivering various bolus caffeine lung doses. Measures of arterial caffeine plasma concentration and post-dosing alertness self-scores (over a 10-point scale) are made following a single inhalation of caffeine.
  • Alertness Patients are asked to rate their alertness on a scale of 0 to 10 pre- and post-dosing. Subjects are anticipated to report an increase in alertness post-dosing relative to pre-dosing. A mean increase in alertness from baseline can be calculated for all three dose levels.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
US14/327,137 2013-07-10 2014-07-09 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same Abandoned US20150013695A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US14/327,137 US20150013695A1 (en) 2013-07-10 2014-07-09 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
US15/957,199 US10632266B2 (en) 2013-07-10 2018-04-19 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
US16/859,241 US20200338281A1 (en) 2013-07-10 2020-04-27 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361844772P 2013-07-10 2013-07-10
US14/327,137 US20150013695A1 (en) 2013-07-10 2014-07-09 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/957,199 Continuation US10632266B2 (en) 2013-07-10 2018-04-19 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same

Publications (1)

Publication Number Publication Date
US20150013695A1 true US20150013695A1 (en) 2015-01-15

Family

ID=51261253

Family Applications (3)

Application Number Title Priority Date Filing Date
US14/327,137 Abandoned US20150013695A1 (en) 2013-07-10 2014-07-09 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
US15/957,199 Active US10632266B2 (en) 2013-07-10 2018-04-19 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
US16/859,241 Abandoned US20200338281A1 (en) 2013-07-10 2020-04-27 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same

Family Applications After (2)

Application Number Title Priority Date Filing Date
US15/957,199 Active US10632266B2 (en) 2013-07-10 2018-04-19 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
US16/859,241 Abandoned US20200338281A1 (en) 2013-07-10 2020-04-27 Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same

Country Status (2)

Country Link
US (3) US20150013695A1 (fr)
WO (1) WO2015006465A1 (fr)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120042889A1 (en) * 2010-03-26 2012-02-23 Philip Morris Usa Inc. Cultured tobacco cells as a matrix for consumable products
US20150020823A1 (en) * 2013-07-19 2015-01-22 Altria Client Services Inc. Liquid aerosol formulation of an electronic smoking article
US20170030883A1 (en) * 2015-07-31 2017-02-02 Electronics And Telecommunications Research Institute Optical oil component sensor and sensing method using the same
WO2017024033A1 (fr) * 2015-08-03 2017-02-09 Atmovita, Llc Compositions et kits pour l'administration en phase gazeuse de composés actifs, procédés de fabrication et méthodes d'utilisation de ces derniers
US9770055B2 (en) 2015-05-15 2017-09-26 Lunatech, Llc Vaporizable material handling for electronic vapor device
US9888725B2 (en) 2015-07-28 2018-02-13 Lunatech, Llc Inhalation puff counter gauge and display system
US9888723B2 (en) 2015-05-15 2018-02-13 Lunatech, Llc Hybrid vapor delivery system utilizing nebulized and non-nebulized elements
US20180084821A1 (en) * 2016-09-27 2018-03-29 BOND STREET MANUFACTURING LLC (a Florida LLC) Vaporizable Tobacco Wax Compositions
US9933790B2 (en) 2015-06-15 2018-04-03 Lunatech, Llc Peer-to-peer air analysis and treatment
US9936737B2 (en) 2015-10-28 2018-04-10 Lunatech, Llc Methods and systems for a dual function vapor device
WO2018073261A1 (fr) * 2016-10-18 2018-04-26 Philip Morris Products S.A. Procédés et systèmes destinés à améliorer la stabilité de la formulation de pré-vapeur d'un dispositif de vapotage électronique
US20180140013A1 (en) * 2016-11-22 2018-05-24 Rai Strategic Holdings, Inc. Rechargeable lithium-ion battery for an aerosol delivery device
US10039320B2 (en) 2015-05-14 2018-08-07 Lunatech, Llc Multi-chambered vaporizer and blend control
US10042369B2 (en) 2015-06-16 2018-08-07 Lunatech, Llc Vapor device for filtering and testing material
US10060639B2 (en) 2015-06-11 2018-08-28 Lunatech, Llc Air analyzer and treatment apparatus
US10065138B2 (en) 2015-06-17 2018-09-04 Lunatech, Llc Remote controllable air treatment apparatus
US10088463B2 (en) 2015-06-11 2018-10-02 Lunatech, Llc Calibrating electronic vapor device
US20180338905A1 (en) * 2017-05-26 2018-11-29 Inhale Health, LLC Bioavailable aerosolized supplement formulations
US10215429B2 (en) 2015-06-15 2019-02-26 Lunatech, Llc Localized air sensing and treatment
US10215430B2 (en) 2015-06-15 2019-02-26 Lunatech, Llc Electronic vapor and analysis with HVAC integration
US10653186B2 (en) 2013-11-12 2020-05-19 VMR Products, LLC Vaporizer, charger and methods of use
WO2020141178A1 (fr) * 2018-12-31 2020-07-09 Philip Morris Products S.A. Préparation de nicotine liquide comprenant un solvant partiellement hydrosoluble
WO2020205676A1 (fr) * 2019-03-29 2020-10-08 V Rush Vapes LLC Composition de suppléments pour athlétisme et entraînement physique, procédé de production et procédé d'administration pulmonaire de celle-ci
WO2022049512A1 (fr) * 2020-09-03 2022-03-10 Rai Strategic Holdings, Inc. Formulation aérosolisable
US11413409B2 (en) 2018-09-12 2022-08-16 Juul Labs, Inc. Vaporizer including positive temperature coefficient of resistivity (PTCR) heating element
CN115227754A (zh) * 2022-06-08 2022-10-25 深圳市吉迩科技有限公司 制备瓜拉纳提取物的方法及含有瓜拉纳提取物的组合物
WO2024057248A1 (fr) * 2022-09-16 2024-03-21 Rai Strategic Holdings, Inc. Formulation aérosolisable
RU2816308C2 (ru) * 2018-12-31 2024-03-28 Филип Моррис Продактс С.А. Жидкий состав на основе никотина, содержащий частично водорастворимый растворитель
WO2024105615A1 (fr) * 2022-11-18 2024-05-23 Rai Strategic Holdings, Inc Formulation aérosolisable

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015006465A1 (fr) * 2013-07-10 2015-01-15 Ahkeo Ventures LLC Compositions inhalables comprenant de la caféine, procédés d'utilisation et appareil permettant d'utiliser ces compositions
GB201817860D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
GB201817868D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Aerosolised formulation
IT202100027086A1 (it) * 2021-10-21 2023-04-21 Alberto Patarchi Erogatore portatile per il trattamento o la prevenzione di un’infezione o di una patologia causata da un virus

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281772A1 (en) * 2004-06-17 2005-12-22 Bromley Philip J Compositions for mucosal delivery of agents
US20060018839A1 (en) * 2002-05-17 2006-01-26 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US7078016B2 (en) * 2001-11-21 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
US20100236562A1 (en) * 2007-06-25 2010-09-23 Alex Hearn Inhalable composition
US20130310422A1 (en) * 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US20140144429A1 (en) * 2012-11-28 2014-05-29 E-Nicotine Technology, Inc. Methods and devices for compound delivery
US20140261474A1 (en) * 2013-03-15 2014-09-18 Aradigm Corporation Methods for inhalation of smoke-free nicotine
US9186350B2 (en) * 2011-07-12 2015-11-17 Gdb Patent Holdings, Llc Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4799700A (en) * 1999-04-27 2000-11-10 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
CN100381083C (zh) 2003-04-29 2008-04-16 韩力 一种非可燃性电子喷雾香烟
CA2601777A1 (fr) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions et procedes pour l'amelioration de la fonction cognitive
EP1965803A1 (fr) * 2005-12-05 2008-09-10 Biomarin Pharmaceutical Inc. Procédés et compositions pour le traitement d'une maladie
EP2113178A1 (fr) * 2008-04-30 2009-11-04 Philip Morris Products S.A. Système de fumée chauffé électriquement avec une portion de stockage liquide
CN201379072Y (zh) 2009-02-11 2010-01-13 韩力 一种改进的雾化电子烟
US8851068B2 (en) * 2009-04-21 2014-10-07 Aj Marketing Llc Personal inhalation devices
US20110015154A1 (en) * 2009-07-20 2011-01-20 Kellermann Gottfried H Supporting acetylcholine function
CN201830899U (zh) * 2010-06-09 2011-05-18 李永海 电子香烟的供电装置
DE202010010189U1 (de) * 2010-07-14 2010-10-14 Frauenheim, Dirk Koffeinhaltige Konzentratlösung in einer Trägerflüssigkeit die mit einem speziellen elektrisch betriebenem einer Zigarette ähnlichem Gerät thermisch verdampft werden kann und dieser koffeinhaltige Dampf inhaliert werden kann
US20150359771A1 (en) * 2013-01-15 2015-12-17 Nusirt Sciences, Inc. Treating pulmonary conditions
WO2014151364A1 (fr) * 2013-03-15 2014-09-25 Buck Institute For Research On Aging Suppléments cognitifs améliorés
WO2015006465A1 (fr) * 2013-07-10 2015-01-15 Ahkeo Ventures LLC Compositions inhalables comprenant de la caféine, procédés d'utilisation et appareil permettant d'utiliser ces compositions
US20160194368A1 (en) * 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078016B2 (en) * 2001-11-21 2006-07-18 Alexza Pharmaceuticals, Inc. Delivery of caffeine through an inhalation route
US20060018839A1 (en) * 2002-05-17 2006-01-26 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20050281772A1 (en) * 2004-06-17 2005-12-22 Bromley Philip J Compositions for mucosal delivery of agents
US20100236562A1 (en) * 2007-06-25 2010-09-23 Alex Hearn Inhalable composition
US20130310422A1 (en) * 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US9186350B2 (en) * 2011-07-12 2015-11-17 Gdb Patent Holdings, Llc Composition, and method of using the composition, effective for minimizing the harmful effects associated with individuals suffering from alcohol intoxication
US20140144429A1 (en) * 2012-11-28 2014-05-29 E-Nicotine Technology, Inc. Methods and devices for compound delivery
US20140261474A1 (en) * 2013-03-15 2014-09-18 Aradigm Corporation Methods for inhalation of smoke-free nicotine

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280396B2 (en) 2010-03-26 2019-05-07 Philip Morris Usa Inc. Cultured tobacco cells as a matrix for consumable products
US11739292B2 (en) 2010-03-26 2023-08-29 Philip Morris Usa Inc. Cultured tobacco cells as a matrix for consumable products
US9862923B2 (en) * 2010-03-26 2018-01-09 Philip Morris Usa Inc. Cultured tobacco cells as a matrix for consumable products
US11339368B2 (en) 2010-03-26 2022-05-24 Philip Morris Usa Inc. Cultured tobacco cells as a matrix for consumable products
US20120042889A1 (en) * 2010-03-26 2012-02-23 Philip Morris Usa Inc. Cultured tobacco cells as a matrix for consumable products
US10660365B2 (en) * 2013-07-19 2020-05-26 Altria Client Services Llc Liquid aerosol formulation of an electronic smoking article
US20150020823A1 (en) * 2013-07-19 2015-01-22 Altria Client Services Inc. Liquid aerosol formulation of an electronic smoking article
US11337453B2 (en) 2013-07-19 2022-05-24 Altria Client Services Llc Liquid aerosol formulation of an electronic smoking article
US11134722B2 (en) 2013-11-12 2021-10-05 Vmr Products Llc Vaporizer
US10667561B2 (en) 2013-11-12 2020-06-02 Vmr Products Llc Vaporizer
US10653186B2 (en) 2013-11-12 2020-05-19 VMR Products, LLC Vaporizer, charger and methods of use
US10980273B2 (en) 2013-11-12 2021-04-20 VMR Products, LLC Vaporizer, charger and methods of use
US11606981B2 (en) 2013-11-12 2023-03-21 Vmr Products Llc Vaporizer
US11051557B2 (en) 2013-11-12 2021-07-06 VMR Products, LLC Vaporizer
US10736360B2 (en) 2013-11-12 2020-08-11 Vmr Products Llc Vaporizer, charger and methods of use
US10039320B2 (en) 2015-05-14 2018-08-07 Lunatech, Llc Multi-chambered vaporizer and blend control
US9888723B2 (en) 2015-05-15 2018-02-13 Lunatech, Llc Hybrid vapor delivery system utilizing nebulized and non-nebulized elements
US9770055B2 (en) 2015-05-15 2017-09-26 Lunatech, Llc Vaporizable material handling for electronic vapor device
US10088463B2 (en) 2015-06-11 2018-10-02 Lunatech, Llc Calibrating electronic vapor device
US10060639B2 (en) 2015-06-11 2018-08-28 Lunatech, Llc Air analyzer and treatment apparatus
US10215429B2 (en) 2015-06-15 2019-02-26 Lunatech, Llc Localized air sensing and treatment
US10215430B2 (en) 2015-06-15 2019-02-26 Lunatech, Llc Electronic vapor and analysis with HVAC integration
US9933790B2 (en) 2015-06-15 2018-04-03 Lunatech, Llc Peer-to-peer air analysis and treatment
US10042369B2 (en) 2015-06-16 2018-08-07 Lunatech, Llc Vapor device for filtering and testing material
US10065138B2 (en) 2015-06-17 2018-09-04 Lunatech, Llc Remote controllable air treatment apparatus
US9888725B2 (en) 2015-07-28 2018-02-13 Lunatech, Llc Inhalation puff counter gauge and display system
US20170030883A1 (en) * 2015-07-31 2017-02-02 Electronics And Telecommunications Research Institute Optical oil component sensor and sensing method using the same
WO2017024033A1 (fr) * 2015-08-03 2017-02-09 Atmovita, Llc Compositions et kits pour l'administration en phase gazeuse de composés actifs, procédés de fabrication et méthodes d'utilisation de ces derniers
US9936737B2 (en) 2015-10-28 2018-04-10 Lunatech, Llc Methods and systems for a dual function vapor device
US20180084821A1 (en) * 2016-09-27 2018-03-29 BOND STREET MANUFACTURING LLC (a Florida LLC) Vaporizable Tobacco Wax Compositions
US10709165B2 (en) * 2016-09-27 2020-07-14 Bond Street Manufacturing Llc Vaporizable tobacco wax compositions
WO2018073261A1 (fr) * 2016-10-18 2018-04-26 Philip Morris Products S.A. Procédés et systèmes destinés à améliorer la stabilité de la formulation de pré-vapeur d'un dispositif de vapotage électronique
US20180140013A1 (en) * 2016-11-22 2018-05-24 Rai Strategic Holdings, Inc. Rechargeable lithium-ion battery for an aerosol delivery device
US10537137B2 (en) * 2016-11-22 2020-01-21 Rai Strategic Holdings, Inc. Rechargeable lithium-ion battery for an aerosol delivery device
EP3630119A4 (fr) * 2017-05-26 2020-12-30 Inhale Health LLC Formulations de suppléments sous forme d'aérosol biodisponibles et méthodes associées
US20180338905A1 (en) * 2017-05-26 2018-11-29 Inhale Health, LLC Bioavailable aerosolized supplement formulations
US11413409B2 (en) 2018-09-12 2022-08-16 Juul Labs, Inc. Vaporizer including positive temperature coefficient of resistivity (PTCR) heating element
US20220079210A1 (en) * 2018-12-31 2022-03-17 Philip Morris Products S.A. Low viscosity liquid nicotine formulation
RU2816308C2 (ru) * 2018-12-31 2024-03-28 Филип Моррис Продактс С.А. Жидкий состав на основе никотина, содержащий частично водорастворимый растворитель
WO2020141184A1 (fr) * 2018-12-31 2020-07-09 Philip Morris Products S.A. Formulation de nicotine liquide à faible viscosité
WO2020141178A1 (fr) * 2018-12-31 2020-07-09 Philip Morris Products S.A. Préparation de nicotine liquide comprenant un solvant partiellement hydrosoluble
CN113163848A (zh) * 2018-12-31 2021-07-23 菲利普莫里斯生产公司 低粘度液体尼古丁制剂
CN113163845A (zh) * 2018-12-31 2021-07-23 菲利普莫里斯生产公司 包含部分水溶性溶剂的液体尼古丁制剂
US20220071270A1 (en) * 2018-12-31 2022-03-10 Philip Morris Products S.A. Liquid nicotine formulation
WO2020141176A1 (fr) * 2018-12-31 2020-07-09 Philip Morris Products S.A. Formulation de nicotine liquide
US11992038B2 (en) 2018-12-31 2024-05-28 Philip Morris Products S.A. Liquid nicotine formulation comprising partially water-soluble solvent
WO2020205676A1 (fr) * 2019-03-29 2020-10-08 V Rush Vapes LLC Composition de suppléments pour athlétisme et entraînement physique, procédé de production et procédé d'administration pulmonaire de celle-ci
WO2022049512A1 (fr) * 2020-09-03 2022-03-10 Rai Strategic Holdings, Inc. Formulation aérosolisable
CN115227754A (zh) * 2022-06-08 2022-10-25 深圳市吉迩科技有限公司 制备瓜拉纳提取物的方法及含有瓜拉纳提取物的组合物
WO2024057248A1 (fr) * 2022-09-16 2024-03-21 Rai Strategic Holdings, Inc. Formulation aérosolisable
WO2024105615A1 (fr) * 2022-11-18 2024-05-23 Rai Strategic Holdings, Inc Formulation aérosolisable

Also Published As

Publication number Publication date
US20190091420A1 (en) 2019-03-28
WO2015006465A1 (fr) 2015-01-15
US20200338281A1 (en) 2020-10-29
US10632266B2 (en) 2020-04-28

Similar Documents

Publication Publication Date Title
US20200338281A1 (en) Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
US20220304980A1 (en) Metered dosing compositions and methods of use of psychedelic compounds
JP4999245B2 (ja) 禁煙を達成するためのシステム
JP5863641B2 (ja) 濃縮肥満細胞安定化用薬学的調合物
US8381739B2 (en) Systems and methods for effecting cessation of tobacco use
CA2691571C (fr) Composition inhalable
RU2421209C2 (ru) Фармацевтические композиции, содержащие циклоспорин
ES2332405T3 (es) Una composicion de nicotina liquida tamponada para administracion pulmonar.
US20160198759A1 (en) E-cigarette or vaping fluid
WO2015120392A1 (fr) Stabilisateurs de membrane utilisés pour le traitement de pneumopathies
WO2008069972A2 (fr) Systèmes destinés à mettre fin à l'usage du tabac
US20080138294A1 (en) Systems and methods for effecting cessation of tobacco use
WO2017178663A1 (fr) Benzodiazépines à usage nasal et inhalées par voie orale
KR20190055057A (ko) 알코올 사용 장애의 치료용 조성물, 장치 및 방법
US20200085831A1 (en) Nasal compositions stimulating ciliary activity
US20200108009A1 (en) Bioavailable aerosolized supplement formulations and methods thereof
Mittal et al. Review on nasal drug delivery system
CN102038991A (zh) 雾(气)化饮料药物
MX2008007291A (en) Pharmaceutical compositions comprising cyclosporin

Legal Events

Date Code Title Description
AS Assignment

Owner name: AHKEO VENTURES LLC, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MCNEAL, KELLY;REEL/FRAME:035583/0934

Effective date: 20130915

Owner name: AHKEO VENTURES LLC, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SKODA, BRENT M.;REEL/FRAME:035583/0988

Effective date: 20150506

Owner name: AHKEO LABS, LLC, PUERTO RICO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AHKEO VENTURES LLC;REEL/FRAME:035585/0580

Effective date: 20150506

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION